Rachel Haurwitz (Caribou)

Ab­b­Vie taps Jen­nifer Doud­na start­up for li­cens­ing deal worth up to $300M for 2 'off-the-shelf' CRISPR-edit­ed CAR-Ts

“Off-the-shelf” CAR-Ts have emerged as a hot-tick­et tar­get in next-gen on­col­o­gy R&D, with Big Phar­mas plac­ing big down pay­ments on nov­el tech. Now, a Cal­i­for­nia biotech play­er found­ed by one of the CRISPR move­ment’s most promi­nent mouth­pieces has added ma­jor drug­mak­er Ab­b­Vie as a team­mate.

Ab­b­Vie will pay Cari­bou Bio­sciences $40 mil­lion in up­front cash and $300 mil­lion in biobucks to de­vel­op two of the biotech’s al­lo­gene­ic CAR-T ther­a­pies, the part­ners said Wednes­day. The biotech will al­so be due roy­al­ty pay­ments for any fu­ture com­mer­cial as­sets.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.